期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卵巢癌组织中KLK9基因的表达及其临床意义 被引量：1

Clinical significance of KLK9 expression in ovarian cancer
下载PDF
导出
摘要 目的:探讨KLK9基因mRNA及其蛋白在卵巢癌组织中的表达及其临床意义。方法:采用半定量RT-PCR和免疫组化SP法检测55例卵巢癌组织KLK9mR-NA及蛋白的表达。结果:KLK9蛋白表达位于细胞质,KLK9mRNA及其蛋白表达水平与临床分期有关;早期卵巢癌(Ⅰ、Ⅱ期)KLK9mRNA及蛋白表达水平明显高于晚期(Ⅲ、Ⅳ期),χ2值分别为7·33及8·69,P值分别为0·006及0·0032。但KLK9mRNA及其蛋白表达水平与病理分级及组织学类型无关。结论:KLK9基因表达可能与卵巢癌的恶性度有关,可作为一项检测卵巢癌预后的指标。 OBJECTIVE:To explore the expression of KLK9 gene and its clinical significance in human ovarian carcinoma. METHODS: RT-PCR and immunohistochemistry were used to detect the expressions of KLK9 mRNA and protein in 55 patients with ovarian cancer. RESULTS: KLK9 protein was detected in the cytoplasm but not in the nuclei of the ovarian cancer cell. Expression of KLK9 both on mRNA and protein levels showed significantly higher in patients with the early stages (Ⅰ or Ⅱ) compared to the advanced stages (Ⅲ or Ⅳ),χ~2=7.33 and 8.69,P=0.006 and 0.003 2. On the other hand, no significant association was found between KLK9 expression grade and histological type of ovarian carcinoma. CONCLUSIONS: The different expression of KLK9 might be related with the malignancy of ovarian carcinoma. KLK9 gene could play a critical role as a prognostic marker in the future.
作者 史玉林 张淑兰 刘丽英 王敏
机构地区 中国医科大学附属二院妇产科 沈阳市妇婴医院妇产科
出处 《肿瘤防治杂志》 2005年第10期738-741,共4页 China Journal of Cancer Prevention and Treatment
基金 辽宁省科技攻关重点项目(2001225002-4)
关键词 卵巢肿瘤 激肽释放酶 分析 逆转录聚合酶链反应 免疫组织化学 ovarian neoplasms kallikrein/analysis reverse transcriptase-polymerase chain reaction immunohistochemistry
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Diamandis E P, Yousef G M, Luo L Y, et al. The new human kallikrein gene family: implications in carcinogenesis[J]. Trends Endocrinol Metab, 2000,11(2):54-60.
  • 2Yousef G M, Diamandis E P. The new human tissue kallikrein gene family: structure, function, and association to disease[J].Endocr Rev, 2001,22(2):184-204.
  • 3Yousef G M, Diamandis E P. The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9) [J]. Genomics, 2000,65(2):184-194.
  • 4Magklara A, Scorilas A, Katsaros D, et al. The human KLK8 (neuropson/ovasin) gene:identification of two novel splice variants and its prognostic value in ovarian cancer[J]. Cancer Res,2001,7(4):806-811.
  • 5武春龙 赵玉兰 吴华星.C—erbB—3在肺癌中的表达及临床意义[J].中华癌症姑息医学杂志,2003,2(2):94-94.
  • 6Meyer T, Rustin G J. Role of tumour markers in monitoring epithelial ovarian cancer [J]. Br J Cancer, 2000,82(9):1535-1538.
  • 7Yousef G M, Kyriakopoalou L G, Scorilas A, et al. Quantitative Expression of the human kallikrein gene(KLK9) in Ovarian Cancer, A new independent and favorable prognostic marker[J].Cancer Res,2001,61:7811-7818.
  • 8Fortier A H, Nelson B.I, Grella D K, et al. Antiangiogenic activity of prostate-specific antigen[J].J Natl Cancer Inst, 1999,91(19):1635-1640.
  • 9Diamandis E P. Prostate-specific antigen or human kallikrein 3.Recent developments[J]. Tumour Biol, 1998,19(2):65-67.
  • 10Goyal J, Smith K M, Cowan J M, et al. The role for NES1 serine. protease as a novel tumor suppressor[J]. Cancer Res, 1998,58(21):4782--4786.

同被引文献13

  • 1Yousef GM, Diamandis EP. The expanded human kallikrein gene family: locus character-zation and molecular cloning of a new member, KLK-L3(KLK9) [J]. Genomics, 2000,65(2) :184-194.
  • 2Lindahl P, Sgll T, Bjartell A, et al. Copy number variants in the kallikrein gene cluster[ J]. PLoS One, 2013,8 (7) : e69097.
  • 3Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissuesand biological fluids [ J ]. Clin Chem, 2007, 53 ( 8 ) : 1423 -1432.
  • 4Radulovic M, Yoon H, Larson N, et al. Kallikrein cascades in traumatic spinal cord injury : in vitro evidence for roles in axonopa- thy and neuron degeneration[J]. Neuropathol Exp Neurol, 2013, 72 ( 11 ) : 1072-1089.
  • 5Shinoda Y, Kozaki K, Imoto I, et al. Association of KLK5 overex- pression with invasiveness of urinary bladder carcinoma cells [ J ]. Cancer Sci, 2007,98(7) :1078-1086.
  • 6Memari N, Grass L, Nakamura T, et al. Human tissue kallikrein 9 : production of recombinant proteins and specific antibodies, Biol [J]. Chem, 2006,387(6) :733-740.
  • 7Yousef GM, Scorilas A, Nakamura T, et al. The prognostic value of the human kallikrein gcne 9 ( KLK9 ) in breast cancer [ J ]. Breast Cancer Res Treat, 2003,78 (2) : 149-158.
  • 8Beaufort N, Debela M, Creutzburg S, et al. Interplay of human tis- sue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR) [ J ]. Biol Chem, 2006, 387(2) :217-222.
  • 9Yoon H, Blaber SI, Debela M, et al. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15 [J]. Biol Chem, 2009,390(4) :373-377.
  • 10包香香,帅茨霞,赵红琴,诸海燕.激肽释放酶5、9与CA125在卵巢癌中的表达及意义[J].山东医药,2008,48(37):94-95. 被引量：3

引证文献1

二级引证文献2

肿瘤防治杂志
2005年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部